NORTHWEST BIOTHERAPEUTICS INC
NWBO · OTCMCIK 1072379fmd_082G8SR4K7A9F08SSAR02PX30MManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 02, 1996 to Jun 30, 2026, 79 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 0 | 0 | 2 | 1 | 1 | 2 | 2 | 1 | 1 |
| Cost of revenue | – | – | – | – | – | – | – | – | – | – |
| Gross profit | – | – | – | – | – | – | – | – | – | – |
| Research and development | 60 | 34 | 18 | 14 | 34 | 20 | 36 | 28 | 35 | 29 |
| Operating income | (79) | (55) | (41) | (28) | (87) | (53) | (67) | (56) | (67) | (60) |
| Interest expense | 4 | 6 | 10 | 3 | 9 | 5 | 6 | 5 | 8 | 9 |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | – | (18) | 6 | 7 | (443) | 232 | (38) | (7) | (17) | (1) |
| Income before taxes | – | – | – | – | – | – | – | – | (84) | (61) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (1) |
| Net income from continuing operations | – | – | – | – | – | – | – | – | (84) | (60) |
| Net income | (80) | (73) | (36) | (21) | (530) | 179 | (105) | (63) | (84) | (60) |
| Net income to common shareholders | (86) | (74) | (54) | (21) | (530) | 179 | (105) | (64) | (85) | (61) |